Brassinin Exhibits Anti-Diabetic Activity against Streptozotocin-induced Diabetes Mellitus in Experimental Rats

Indian Journal of Pharmaceutical Education and Research

  • Bixia Xu1Teaching and Research Section of Internal Medicine, Zhaoqing Medical College, Guangdong Province, CHINA.
  • Abdullah A. Alarfaj2Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, SAUDI ARABIA.
  • Abdurahman Hajinur Hirad2Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, SAUDI ARABIA.
  • Nandakumar Natarajan3Department of Cellular and Molecular Biology, University of Texas at Tyler Health Science Center, Tyler, TEXAS, USA.
  • Petchi Iyappan4Faculty of Medicine, Bioscience and Nursing, Mahsa University, Saujana Putra, MALAYSIA.
  • Samer Hasan Hussein Al Ali5Department of Chemistry, Faculty of Science, Isra University, Amman, JORDAN.

Volume 57 Issue 3s Pages s701-s709

DOI: 10.5530/ijper.57.3s.79

Abstract

Background: Diabetes mellitus is among the most serious public health problems worldwide. Materials and Methods: 35mg/kg STZ was injected to rats for stimulating diabetes. Then rats were treated with 25mg/kg of brassinin. Results: Brassinin and Glibenclamide remarkably decreased glucose and HbA1c levels in diabetic rats, while insulin levels were elevated. They also increased antioxidant enzymes and decreased inflammatory markers. Conclusion: Brassinin is an antihyperglycemic, antioxidant, and anti-inflammatory compound that protects the liver, kidney, and pancreas during diabetes.

Keywords

  • Brassinin
  • Glycosylated haemoglobin
  • Oxidative stress
  • Inflammation
IJOPP

Loading…